Skip to main content
. 2021 Dec 23;9(12):e002843. doi: 10.1136/jitc-2021-002843

Figure 3.

Figure 3

Intratumoral injection of VV-scFv-TIGIT enhanced infiltration of immune cells in the CT26 tumor model. (A) Treatment scheme of CT26 subcutaneous (S.C.) tumor model. (B) Mean tumor volume of mice. (C) Individual tumor growth curve of mice. (D) Body weight of mice. (E) Representative diagram of flow cytometric analysis of immune cell infiltration in tumor tissues. (F) Flow cytometric analysis of the proportion of lymphocytes and their subpopulations in tumor tissues. (G) Flow cytometric analysis of the expression of immune checkpoints on CD8+ T cells. (H) Flow cytometric analysis of the expression of immune checkpoints on CD4+ T cells. (I) Flow cytometric analysis of the expression of CD107A on CD8+ T cells. (J) Flow cytometric analysis of the proportion of lymphocytes subsets in splenocytes. (K) The virus titers in tumor tissues or sera of mice were quantified by the TCID50 method. ns, no significant differences; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. PBS, phosphate-buffered saline; scFv, single-chain variable fragment; TIGIT, T-cell immunoglobulin and ITIM domain; VV, vaccinia virus.